|
⚲
|
| Keyboard |
| Aspicio Therapeutics Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0002025735 |
| Sale | 2026-07-16 (0.2 M Offered, 0.2 M Sold) |
| Fund | |
| Phone | 4848854744 |
| Address | 250 Truman Way Downingtown, PA 19335 |
| Source | [EDGAR] |
| Amount Raised ($k) |
|---|
| Company Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Form D Offering | |
|---|---|
| Filed | 2026-07-17 (D) |
| Exemption | 506(b) |
| Duration | One year or less |
| Revenue | Decline to Disclose |
| Directors | Role | 2011 - 2026 |
|---|---|---|
| Michael Keane | Executive Officer |
| Comparable Firms | State | AUM |
|---|---|---|
|
Dark Horse Capital Management LLC
✚
|
PA | |
|
Aberdeen Standard Investments Inc
✚
|
PA | |
|
Veritable LP
✚
|
PA | |
|
Horton Capital Management LLC
✚
|
PA | |
|
Susquehanna International Group LLP
✚
|
PA | |
|
Marathon Trading Investment Management LLC
✚
|
PA | |
|
Seamark Capital LP
✚
|
PA | |
|
Strategos Capital Management LLC
✚
|
PA | |
|
Quaker Capital Management Corp
✚
|
PA | |
|
Delaware Management Business Trust
✚
|
PA |